2374124-49-7
Chemical Structure
Vanzacaftor
Synonym(s): VX-121
- No. CAS: 2374124-49-7
- Formula:C32H39N7O4S
- Molecular Weight:617.76
IUPAC Name: (Z)-2-(4-(3-(2-chloro-9H-thioxanthen-9-ylidene)propyl)piperazin-1-yl)ethan-1-ol dihydrochloride
InChIKey: VCSUIBJKYCVWNF-NRFANRHFSA-N
SMILES: CC(C)(C[C@@](CCC/N=C1NC(S(=O)(N2)=O)=CC=C\1)([H])C3)N3C4=NC(N(C=C5)N=C5OCCC6C7(CC7)C68CC8)=CC=C4C2=O
Biological Activity: Vanzacaftor (VX-121) is an orally active noval corrector of Cystic fibrosis transmembrane conductance regulator (CFTR). Vanzacaftor improves processing and trafficking of CFTR protein as well as increases chloride transport in triple combined with Tezacaftor (HY-15448) and Deutivacaftor. Vanzacaftor-Tezacaftor-Deutivacaftor is safe and well tolerated, improving lung function, respiratory symptoms, and CFTR function with cystic fibrosis, which is promising for research in the field of cystic fibrosis diseases[1][2].
| Referencia número | Nombre del producto | Pureza | Descripciòn | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Vanzacaftor | 98.72% | Vanzacaftor (VX-121) is an orally active noval corrector of Cystic fibrosis transmembrane conductance regulator (CFTR). Vanzacaftor improves processing and trafficking of CFTR protein as well as increases chloride transport in triple combined with Tezacaftor (HY-15448) and Deutivacaftor. Vanzacaftor-Tezacaftor-Deutivacaftor is safe and well tolerated, improving lung function, respiratory symptoms, and CFTR function with cystic fibrosis, which is promising for research in the field of cystic fibrosis diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Vanzacaftor-d4 | Vanzacaftor-d4 (VX-121-d4) is the deuterium labeled Vanzacaftor (HY-145603). Vanzacaftor is an orally active noval corrector of Cystic fibrosis transmembrane conductance regulator (CFTR). Vanzacaftor improves processing and trafficking of CFTR protein as well as increases chloride transport in triple combined with Tezacaftor (HY-15448) and Deutivacaftor. Vanzacaftor-Tezacaftor-Deutivacaftor is safe and well tolerated, improving lung function, respiratory symptoms, and CFTR function with cystic fibrosis, which is promising for research in the field of cystic fibrosis diseases. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 1.00
HY-145603A(R)-Vanzacaftor -
Similarity Score 0.53
HY-126394Bamocaftor -
Similarity Score 0.53
HY-126394BBamocaftor potassium -
Similarity Score 0.49
HY-111772A(R)-Elexacaftor -
Similarity Score 0.49
HY-111772RElexacaftor (Standard) -
Similarity Score 0.42
HY-162234PKCθ-IN-3 -
Similarity Score 0.41
HY-158045PROTAC PARP1 degrader-1 -
Similarity Score 0.41
HY-181115EGFR-IN-193 -
Similarity Score 0.41
HY-164978KIF18A-IN-14 -
Explore the MedChemAI to find more analogs
References
- [1]. Uluer AZ, et al. Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials[J]. Lancet Respir Med. 2023 Jun;11(6):550-562. [Content Brief]
- [2]. Kolski-Andreaco A, et al. Potentiation of BKCa channels by cystic fibrosis transmembrane conductance regulator (CFTR) correctors VX-445 and VX-121[J]. J Clin Invest. 2024 Jul 2:e176328. [Content Brief]
